Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amur Minerals ( (GB:CRTX) ) has issued an announcement.
CRISM Therapeutics Corporation has successfully raised £800,000 through a placing of new ordinary shares to fund the development of its ChemoSeed drug delivery platform. The proceeds will support the manufacturing and clinical trial setup for a Phase 2 trial in glioblastoma, with the first patients expected to be dosed in early 2026. This funding marks a significant step in CRISM’s efforts to advance its novel treatment for this aggressive form of brain cancer, reflecting strong investor confidence and providing an opportunity for existing shareholders to participate in a forthcoming retail offer.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based company specializing in innovative drug delivery technologies aimed at enhancing the clinical performance of cancer treatments for solid tumors. Their lead product, ChemoSeed, is designed for localized delivery of chemotherapy drugs, particularly targeting high-grade glioma by bypassing the blood-brain barrier.
Average Trading Volume: 67,074
Technical Sentiment Signal: Strong Buy
Current Market Cap: £1.83M
For a thorough assessment of CRTX stock, go to TipRanks’ Stock Analysis page.